Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 496

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia

Etienne, Gabriel, Guilhot, Joëlle, Rea, Delphine, Rigal-Huguet, Françoise, Nicolini, Franck, Charbonnier, Aude, Guerci-Bresler, Agnès, Legros, Laurence, Varet, Bruno, Gardembas, Martine, Dubruille, Viviane, Tulliez, Michel, Noel, Marie-Pierre, Ianotto, Jean-Christophe, Villemagne, Bruno, Carré, Martin, Guilhot, François, Rousselot, Philippe, Mahon, François-Xavier·2017·Journal of Clinical Oncology

Abstract

Purpose: Imatinib (IM) can safely be discontinued in patients with chronic myeloid leukemia (CML) who have had undetectable minimal residual disease (UMRD) for at least 2 years. We report the final results of the Stop Imatinib (STIM1) study with a long follow-up. Patients and Methods: IM was prospectively discontinued in 100 patients with CML with UMRD sustained for at least 2 years. Molecular recurrence (MR) was defined as positivity of BCR-ABL transcript in a quantitative reverse transcriptase polymerase chain reaction assay confirmed by a second analysis point that indicated an increase of one log in relation to the first analysis point at two successive assessments or loss of major molecular response at one point. Results: The median molecular follow-up after treatment discontinuation was 77 months (range, 9 to 95 months). Sixty-one patients lost UMRD after a median of 2.5 months (range, 1 to 22 months), and one patient died with UMRD at 10 months. Molecular recurrence-free survival was 43% (95% CI, 33% to 52%) at 6 months and 38% (95% CI, 29% to 47%) at 60 months. Treatment was restarted in 57 of 61 patients with MR, and 55 patients achieved a second UMRD with a median time of 4 months (range, 1 to 16 months). None of the patients experienced a CML progression. Analyses of the characteristics of the study population identified that the Sokal risk score and duration of IM treatment were significantly associated with the probability of MR. Conclusion: With a median follow-up of more than 6 years after treatment discontinuation, the STIM1 study demonstrates that IM can safely be discontinued in patients with a sustained deep molecular response with no late MR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2016.68.2914

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 496

Metadata

Authors
Etienne, G., Guilhot, J., Rea, D., Rigal-Huguet, F., Nicolini, F., Charbonnier, A., Guerci-Bresler, A., Legros, L., Varet, B., Gardembas, M., Dubruille, V., Tulliez, M., Noel, M.-P., Ianotto, J.-C., Villemagne, B., Carré, M., Guilhot, F., Rousselot, P., & Mahon, F.-X.
Venue
Journal of Clinical Oncology
Published
2017-01-20
Volume
35
Issue
3
Pages
298-305
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2528188718
Cited by
496
References
29
FWCI
41.87
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. https://app.cochat.ai/papers/10.1200/jco.2016.68.2914
The paper
Etienne, G., Guilhot, J., Rea, D., Rigal-Huguet, F., Nicolini, F., Charbonnier, A., Guerci-Bresler, A., Legros, L., Varet, B., Gardembas, M., Dubruille, V., Tulliez, M., Noel, M.-P., Ianotto, J.-C., Villemagne, B., Carré, M., Guilhot, F., Rousselot, P., & Mahon, F.-X. (2017). Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.68.2914

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.